Abstract
We appreciate the comments on our article by Drs. Oaklander and Dalakas.1 We agree that immune-related forms of painful small fiber neuropathy (SFN) could potentially benefit from IV immunoglobulins (IVIg), and as mentioned, there are case series that underline the positive effect of IVIg. The group of autoimmune-related SFN was not the focus of our study. Our study cohort was targeted on patients with I-SFN because no underlying condition is found in 53% of the SFN population, which is a large proportion of clinical patients and clinically relevant.2
Full Text
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call